Lv1
40 积分 2026-01-05 加入
Drug-induced enzyme activity inhibition and CYP3A4 genetic polymorphism significantly shape the metabolic characteristics of furmonertinib
4天前
已完结
Simultaneous determination of alflutinib and its active metabolite in human plasma using liquid chromatography–tandem mass spectrometry
8天前
已完结
Three Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Similarities and Differences
9天前
已完结
Evaluation of the pharmacokinetic effects of itraconazole on alflutinib (AST2818): an open-label, single-center, single-sequence, two-period randomized study in healthy volunteers
15天前
已完结
[Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2024 edition)]
29天前
已完结
Furmonertinib: First Approval
29天前
已完结
Single-dose clinical pharmacokinetic studies of gefitinib
1个月前
已完结
FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience
3个月前
已关闭
FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies
3个月前
已完结
皖公网安备34019202002308
